Business Segments · Allowance for credit loss, writeoff
U.S. Pharmaceutical — Allowance for credit loss, writeoff
McKesson U.S. Pharmaceutical — Allowance for credit loss, writeoff remained flat by 0.0% to $59.25M in Q4 2025 compared to the prior quarter. This is a positive signal — lower values indicate better performance for this metric.
Analysis
StatementSegment
CategoryRisk
SignalLower is better
VolatilityModerate
First reportedQ1 2019
Last reportedQ4 2025
How to read this metric
An increase suggests deteriorating credit quality among pharmacy or hospital customers, while a decrease indicates stable or improving customer solvency.
Detailed definition
This represents the actual amount of accounts receivable written off during the period within the U.S. Pharmaceutical se...
Peer comparison
Standard across pharmaceutical wholesalers like Cencora and Cardinal Health as a measure of credit risk exposure.
Metric ID:
mck_segment_u_s_pharmaceutical_allowance_for_credit_loss_writeoffHistorical Data
1 years
| FY'25 | |
|---|---|
| Value | $237.00M |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is McKesson's u.s. pharmaceutical — allowance for credit loss, writeoff?
- McKesson (MCK) reported u.s. pharmaceutical — allowance for credit loss, writeoff of $59.25M in Q4 2025.
- What does u.s. pharmaceutical — allowance for credit loss, writeoff mean?
- The total value of customer debts deemed uncollectible and removed from the books during the period.